Cartesian Therapeutics Inc. (RNAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has a cash flow conversion efficiency ratio of 0.149x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.14 Million) by net assets ($-148.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cartesian Therapeutics Inc. balance sheet quality to measure how much of total assets are equity-financed.
Cartesian Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Cartesian Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Cartesian Therapeutics Inc. to evaluate the quality of earnings relative to operating cash generation.
Cartesian Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIRO Group Holdings, Inc. Common Stock
NASDAQ:AIRO
|
-0.008x |
|
Clavister Holding AB (publ.)
ST:CLAV
|
-0.204x |
|
Bien Yapi Urunleri Sanayi Turizm ve Ticaret A.S.
IS:BIENY
|
-0.017x |
|
New World Resources Ltd
AU:NWC
|
-0.015x |
|
Lucara Diamond Corp
TO:LUC
|
0.083x |
|
Sparebank 1 Nordvest
OL:SNOR
|
-0.029x |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
-0.166x |
|
Vizsla Royalties Corp.
V:VROY
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Cartesian Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Cartesian Therapeutics Inc. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Cartesian Therapeutics Inc. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-126.24 Million | $-73.94 Million | 0.586x | -83.17% |
| 2024-12-31 | $-6.80 Million | $-23.67 Million | 3.480x | +2894.54% |
| 2023-12-31 | $-440.18 Million | $-51.16 Million | 0.116x | +134.48% |
| 2022-12-31 | $93.83 Million | $-31.63 Million | -0.337x | +87.43% |
| 2021-12-31 | $22.52 Million | $-60.38 Million | -2.681x | -38.40% |
| 2020-12-31 | $-18.01 Million | $34.88 Million | -1.937x | +68.37% |
| 2019-12-31 | $8.40 Million | $-51.44 Million | -6.125x | -156.10% |
| 2018-12-31 | $-5.42 Million | $-59.16 Million | 10.919x | +1187.25% |
| 2017-12-31 | $51.81 Million | $-52.04 Million | -1.004x | -180.41% |
| 2016-12-31 | $54.96 Million | $-19.68 Million | -0.358x | -285.74% |
| 2015-12-31 | $-116.49 Million | $-22.46 Million | 0.193x | +33.39% |
| 2014-12-31 | $-87.75 Million | $-12.69 Million | 0.145x | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more